Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback